Mark S. Hixon

Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain Complexed with Small-Molecule Inhibitors Highlight Active-Site Flexibility

N.R. Silvaggi, Grant E. Boldt, Mark S. Hixon et al. · Chemistry & Biology · 2007 · 128 citations

Microbial Toxin, Toxinology, Biochemistry +3

An <i>in vitro</i> and <i>in vivo</i> disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists

Lisa M. Eubanks, Mark S. Hixon, Wei Jin et al. · Proceedings of the National Academy of Sciences · 2007 · 120 citations · Full text

Lead Compounds, Immunotoxicology, Toxinology +18

The Mechanism of Class II, Metal‐Dependent Aldolases

Wolf‐Dieter Fessner, Achim Schneider, Heike A. Held et al. · Angewandte Chemie International Edition in English · 1996 · 107 citations

Molecular Pharmacology, Class Ii, Zn2+-dependent Aldolases +12

Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein

Debra Van Egeren, Alexander Novokhodko, Madison Stoddard et al. · PLoS ONE · 2021 · 95 citations · Full text

Biomedical Interventions, Viral Pathogenesis, Immunology +18

Metabolomics-Based Discovery of Diagnostic Biomarkers for Onchocerciasis

Judith R. Denery, Ashlee A. K. Nunes, Mark S. Hixon et al. · PLoS neglected tropical diseases · 2010 · 81 citations · Full text